Visitation Alert


Palbociclib in Treating Patients W/Relapsed or Refractory Rb Positive Advanced Solid Tumors, NHL, or Histiocytic Disorders W/Activating Alterations in Cell Cycle Genes (Pediatric MATCH)

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes

  • Clinical Trial Information

    Trial Contact: Spinelli, Jennifer; Leffin, Melissa; El-Shami, Jessica

  • IRB No: APEC1621I

    Protocol Abbrev: APEC1621I

    Principal Investigator: Amy A Smith, MD

    Phase: Drug: Phase II

    Age Group: Adult;Pediatric

    Secondary Protocol No: APEC1621I

    Treatment: Other: Laboratory Biomarker Analysis; Drug: Palbociclib; Other: Pharmacological Study

    Therapies Involved: Chemotherapy ID: NCT03526250

  • Objective

    To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with palbociclib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in cell cycle genes.

  • Key Eligibility

    Ages Eligible for Study: 12 Months to 21 Years (Child, Adult)
    Sexes Eligible for Study: All
    Accepts Healthy Volunteers: No